Tempus AI, Inc.

TEM

Nasdaq; business equipment; SIC 7370, Services-Computer Programming, Data Processing, Etc.; CIK 0001717115

None

No letter

3 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $2.3B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	thin data not computable: dilution, distress, fortress balance sheet
Inputs computable	3 of 14
Graded from	filings received through Feb 24, 2026 244 days before the rescan; latest periodic filing 10-Q received Jul 30, 2026
Last close	$67.61 2026-10-23; market equity $0; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 24, 2026

We endeavor to unlock the true power of precision medicine by creating Intelligent Diagnostics through the practical application of artificial intelligence, or AI, in healthcare. Intelligent Diagnostics use AI, including generative and agentic AI, to make laboratory tests more accurate, tailored, and personal. We make tests intelligent by connecting laboratory results to a patient's own clinical data, thereby personalizing the results.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 81.7						
Gross profitability	not computable	28.6%				
one or more required annual facts are missing						
Return on invested capital	not computable	11.2%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(1.7%)	(7.3%)	81.7	620	2025-12-31
Gross margin stability, five years	not computable	2.3 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 47.6					
Twelve-month failure probability	not computable	0.05%			
liabilities and a nearby cover-page share count are required at 2026-06-30					
Altman Z double-prime	(1.60)	2.15	65.5	567	2025-12-31
Net debt to EBITDA	not computable	1.11x			
one or more required annual facts are missing					
Interest coverage	not computable	3.77x			
one or more required annual facts are missing					
Current ratio	3.13x	2.01x	29.6	664	2025-12-31
Growth and financing					
Revenue growth, three-year compound	not computable	6.4%			
four annual observations are required; found 2					
Free cash flow growth, three-year compound	not computable	18.1%			
four consecutive annual FCF observations are required; found 2					
Reinvestment rate	not computable	14.3%			
NOPAT must exceed $100,000					
Asset growth, three years	not computable	5.1%			
four annual observations are required; found 2					
Net share issuance, one year	not computable	0.5%			
two annual share counts are required; found 0					

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	3 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-10-23 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(21.9%)	2.2%	30
Distance from 52-week high	(26.2%)	(32.8%)	59
EBIT to enterprise value	not computable	1.6%	
Free cash flow yield	not computable	2.9%	
Book value to price	not computable	0.26	
Sales to price	not computable	0.32	
Composite equity issuance, five years	not computable	4.2%	
Relative strength against the sector, log excess return	(0.53)	(0.26)	30

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$599.6M
Operating cash flow, four quarters	-$237.4M
Months of runway	30.3
Days since last periodic filing	88 (10-Q received Jul 30, 2026)
Median daily dollar volume, 63 sessions	$388.1M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$245.0M	2025-12-31	2026-02-24	10-K	26-066961
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$218.1M	2025-12-31	2026-02-24	10-K	26-066961
3	assets	us-gaap:Assets	$2.3B	2025-12-31	2026-02-24	10-K	26-066961
4	assets	us-gaap:Assets	$926.1M	2024-12-31	2026-02-24	10-K	26-066961
5	current assets	us-gaap:AssetsCurrent	$1.2B	2025-12-31	2026-02-24	10-K	26-066961
6	current liabilities	us-gaap:LiabilitiesCurrent	$372.4M	2025-12-31	2026-02-24	10-K	26-066961
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$2.4B	2025-12-31	2026-02-24	10-K	26-066961
8	operating income	us-gaap:OperatingIncomeLoss	-$252.9M	2025-12-31	2026-02-24	10-K	26-066961
9	book equity	us-gaap:StockholdersEquity	$491.3M	2025-12-31	2026-02-24	10-K	26-066961
10	liabilities	us-gaap:Liabilities	$1.8B	2025-12-31	2026-02-24	10-K	26-066961
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.3B	2025-12-31	2026-02-24	10-K	26-066961
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$693.4M	2024-12-31	2026-02-24	10-K	26-066961
13	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$21.0M	2025-12-31	2026-02-24	10-K	26-066961
14	depreciation amortization	us-gaap:Depreciation	$32.1M	2025-12-31	2026-02-24	10-K	26-066961
15	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$291.1M	2025-12-31	2026-02-24	10-K	26-066961
16	income tax	us-gaap:IncomeTaxExpenseBenefit	-$51.7M	2025-12-31	2026-02-24	10-K	26-066961
17	current assets	us-gaap:AssetsCurrent	$667.6M	2024-12-31	2026-02-24	10-K	26-066961
18	current liabilities	us-gaap:LiabilitiesCurrent	$291.1M	2024-12-31	2026-02-24	10-K	26-066961

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.